# Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
Canonical URL: https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-to-announce-corporate-update-and-fourth-quarter-and-full-y-dfa2a4d4
Ticker: QNRX
Company: Quoin
Source: Quoin
Published: 2026-03-19 12:30 EST
## Summary

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty...

## Article Body
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025.

About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

For further information, contact: Quoin Pharmaceuticals Ltd. Michael Myers, Ph.D., CEO mmyers@quoinpharma.com

Investor Relations PCG Advisory Jeff Ramson jramson@pcgadvisory.com (646) 863-6341
## Recent Company News
- 2026-07-09 12:30 EST — [Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of  QRX003 in Peeling Skin Syndrome](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-receives-fda-ind-clearance-to-initiate-phase-2-study-of-qr-16d52698) — Source: Quoin
- 2026-06-30 12:30 EST — [Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-receives-u-s-notice-of-allowance-for-patent-covering-combi-9c801c3f) — Source: Quoin
- 2026-06-23 12:30 EST — [Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-receives-fda-conditional-approval-of-qyleki-as-the-propose-52762b71) — Source: Quoin
- 2026-06-18 12:30 EST — [Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-completes-establishment-of-japanese-subsidiary-to-advance--cbcbe641) — Source: Quoin
- 2026-06-16 12:30 EST — [Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program](https://biopharmsignal.com/news/QNRX/quoin-pharmaceuticals-announces-positive-clinical-update-from-ongoing-pediatric--1dca0871) — Source: Quoin
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)